Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced <i>EGFR</i>-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.

Transl Lung Cancer Res · 2023 · PMC10713260 · PMID 38090527

Europe PMC DOI

hedged sentence

0.4420

closest p · 8.8× alpha

0.4420

boldest claim

The sentences

did not reach statistical significanceP=0.442not close (p > 0.1)

In the FLAURA China subgroup analysis, the osimertinib group exhibited a trend towards prolonged OS, although it did not reach statistical significance (33.1 vs. 25.7 months; P=0.442) ( 19 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.